NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today the pricing of its previously announced public offering of 2,250,000 shares of common stock, representing 1,500,000 newly issued shares to be sold by the Company and 750,000 shares to be sold by selling stockholders, at a price of $32.00 per share. The Company is expected to receive net proceeds of approximately $44.4 million from the sale of its common stock and will not receive any proceeds from the sale of shares by the selling stockholders.
